DDInter1607 DDInter183
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secnidazole
Secnidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Benznidazole
Ritonavir {u} (Compound) causes {v} (Side Effect) Myositis
Myositis {u} (Side Effect) is caused by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Benznidazole
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ritonavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Benznidazole
Ritonavir (Compound) causes Myositis (Side Effect) and Myositis (Side Effect) is caused by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Benznidazole